Explore our turnkey product pipelines, advanced pharmacological screening programs, and bio-fractionated active ingredients engineered to meet the strictest United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) specifications.
Providing evidence-based contract development, validation, and manufacturing to resolve the world's most intricate herbal chemistry obstacles.
How our vertically unified agronomy, pilot extraction arrays, and regulatory testing infrastructure eradicate raw material fluctuations, pesticide risks, and supply fragmentation.
China holds over 11,000 recorded medicinal plant species. Our direct raw-material cooperatives across specialized micro-climates ensure our ODM natural components derive from indigenous geographic belts (Daodi herbs), maximizing concentration gradients of primary bio-metabolites.
Our pilot plants incorporate industrial subcritical solvent arrays, CO2 supercritical extraction, macroporous resin adsorption, and continuous molecular distillation. We separate bioactive fractions without thermal degradation or organic residue build-ups.
Scaling botanical synthesis requires extensive steam, thermal management, and analytical cycles. By managing full pilot-to-bulk industrial lines in Hunan, we deliver 30% to 50% cost reductions relative to Western CDMO equivalents while exceeding USP purity specs.
Inconsistent bioactive concentrations in raw natural matrices often undermine commercial formulations. MedGence solves this challenge by implementing longitudinal seasonal mapping. By assessing plants across harvest cycles (spring emergent leaves vs. autumn root systems) and cross-referencing soil chemistry through ICP-MS mineral indexing, we standardize secondary metabolite production (e.g., ginsenosides, baicalin, salvianolic acid B) within strict ±2% variance thresholds.
Navigating FDA cGMP 21 CFR 111/211, EFSA Novel Food guidelines, and strict pharmacopeia monograph validations to ensure zero customs and testing friction worldwide.
Every commercial lot is certified against heavy metal toxicities (Lead, Arsenic, Cadmium, Mercury under ICP-MS), organochlorine pesticide residues via GC-MS/MS, aflatoxins (B1, B2, G1, G2), and microbial limits compliant with EP 5.1.8 regulations.
We provide full CMC (Chemistry, Manufacturing, and Controls) support, Certificate of Analysis (CoA) transparency, Drug Master File (DMF) technical packages, and validation datasets required by global health authorities for Dietary Supplement and Botanical Drug Applications.
To eliminate cross-border lead times, MedGence partners with localized distribution hubs across North America, the European Union, and Southeast Asia. Clients receive domestic-level logistics, localized import compliance, and lot re-testing guarantees.
From single-molecule clinical research to high-shelf-life retail nutraceutical lines, our formulations are optimized for bioavailability, stability, and customer adherence.
Designed for biotech innovators advancing natural lead compounds through preclinical and Phase I–IV trials. We deliver validated analytical fingerprints (HPTLC/HPLC-DAD), GLP animal safety summaries, pharmacokinetic (PK/PD) data, and pilot drug substance validation.
Engineered for brands producing solid oral dosage forms (capsules, tablets, enteric-coated softgels) and functional beverages. We solve common botanical formulation hurdles like hygroscopicity, poor water solubility, bitter astringency, and oxygen sensitivity.
Supplying water-dispersible, decolorized, and odor-optimized plant active extracts for dermal serums and anti-aging lotions. All cosmetic batches undergo in vitro keratinocyte proliferation testing, elastase inhibition verification, and transdermal permeation optimization.
Direct answers covering contract scope, intellectual property protection, regulatory documentation, and production scalability for international enterprise procurement.
An ingredient broker merely trades bulk commodities. As a dedicated CRO/CDMO, MedGence conducts target molecule identification, develops and validates analytical methods (HPTLC, HPLC, GC), runs preclinical cellular and animal trials, formulates stable matrices, and manufactures finished dosage forms with complete IP protection.
We work exclusively under enforceable, bi-lingual Non-Disclosure and Entrusted Development Agreements. All project data, chromatography methodologies, and customized pilot scale processes belong strictly to the client, ring-fenced from competitors.
We deploy high-performance liquid chromatography (HPLC with DAD/ELSD/FLD), gas chromatography with mass spectrometry (GC-MS/MS), high-performance thin-layer chromatography (HPTLC), UV-Vis spectrophotometry, and ICP-MS for elemental impurities to ensure cross-batch consistency.
Yes. Our medical team conducts small-group human nutritional trials for dietary supplement claim substantiation as well as full GCP-compliant Phase I through Phase IV clinical safety and efficacy studies for pharmaceutical Botanical Drug Applications.
Active natural ingredients can be supplied as freeze-dried or spray-dried powders, standardized pastes, concentrated liquids, and volatile oils. Finished consumer products include hard capsules, enteric softgels, multilayer tablets, oral liquids, and effervescent granules.
We perform seasonal and origin-based potency benchmarking. By collecting raw botanicals during optimal phenolic windows and running multi-compound chromatographic fingerprints, we standardize raw inputs and adjust extraction ratios to maintain constant potency.
The global pharmaceutical and clinical wellness sectors are rapidly shifting from synthetic monosubstances toward complex, synergistic botanical active components.
Global regulatory bodies no longer accept historical anecdotes alone. Sustainable growth requires transcriptomic and metabolomic validation. Modernizing traditional formulas through in vitro bioassays helps substantiate physiological pathways for cardiovascular, cognitive, and metabolic outcomes.
Eliminating chlorinated solvents and adopting enzyme-assisted aqueous processes, supercritical CO2, and recyclable resin chromatography are critical for brand equity. Our green extraction frameworks preserve molecular integrity while lowering greenhouse gas footprints.
Adulteration remains a significant risk in international botanical procurement. By integrating orthogonal DNA barcoding with chromatographic fingerprinting, MedGence guarantees complete species integrity and guards against cross-contamination or filler inclusion across every commercial consignment.
Accelerate development cycles from benchtop molecular characterization to certified multi-ton contract supply with our standardized core offerings.
Our validated extraction profiles and clinical trial execution power products developed by industry leaders across China and international healthcare markets.
Tongrentang Group
CR Sanjiu
Sunflower Pharma
Livzon Pharma
Dihon Pharma
Golden Throat Group
Yangtzi River Pharma
Gofar Chuanshan Bio
Humanwell Healthcare
SCIMYTH Pharma
Hanfang Pharma
Luoxin Pharma